

GUT Product References



Guglielmetti, S., Mora, D., Gschwender, M., & Popp, K. (2011). Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study. *Alimentary pharmacology & therapeutics*, 33(10), 1123–1132. <https://doi.org/10.1111/j.1365-2036.2011.04633.x>

Del Re, B., Sgorbati, B., Miglioli, M., & Palenzona, D. (2000). Adhesion, autoaggregation and hydrophobicity of 13 strains of Bifidobacterium longum. *Letters in applied microbiology*, 31(6), 438-442.

Nagaoka, M., Shibata, H., Kimura, I., Hashimoto, S., Kimura, K., Sawada, H., & Yokokura, T. (1995). Structural studies on a cell wall polysaccharide from Bifidobacterium longum YIT4028. *Carbohydrate research*, 274, 245-249.

Arunachalam, K., Gill, H. S., & Chandra, R. K. (2000). Enhancement of natural immune function by dietary consumption of Bifidobacterium lactis (HN019). *European Journal of Clinical Nutrition*, 54(3), 263-267.

Ahmed, M., Prasad, J., Gill, H., Stevenson, L., & Gopal, P. (2007). Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects. *Journal of Nutrition Health and Aging*, 11(1), 26.

Ringel-Kulka, T., McRorie, J., & Ringel, Y. (2017). Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the benefit of the probiotic Bifidobacterium infantis 35624 in non-patients with symptoms of abdominal discomfort and bloating. *Official journal of the American College of Gastroenterology/ACG*, 112(1), 145-151.

Brenner, D. M., & Chey, W. D. (2009). Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome. *Rev Gastroenterol Disord*, 9(1), 7-15.

Natividad, J. M., Hayes, C. L., Motta, J. P., Jury, J., Galipeau, H. J., Philip, V., Garcia-Rodenas, C. L., Kiyama, H., Bercik, P., & Verdu, E. F. (2013). Differential induction of antimicrobial REGIII by the intestinal microbiota and *Bifidobacterium breve* NCC2950. *Applied and environmental microbiology*, 79(24), 7745–7754. <https://doi.org/10.1128/AEM.02470-13>

Sagar, S., Morgan, M. E., Chen, S., Vos, A. P., Garssen, J., van Bergenhenegouwen, J., Boon, L., Georgiou, N. A., Kraneveld, A. D., & Folkerts, G. (2014). *Bifidobacterium breve* and *Lactobacillus rhamnosus* treatment is as effective as budesonide at reducing inflammation in a murine model for chronic asthma. *Respiratory research*, 15(1), 46. <https://doi.org/10.1186/1465-9921-15-46>

María Remes Troche, J., Coss Adame, E., Ángel Valdovinos Díaz, M., Gómez Escudero, O., Eugenia Icaza Chávez, M., Antonio Chávez-Barrera, J., Zárate Mondragón, F., Antonio Ruíz Velarde Velasco, J., Rafael Aceves Tavares, G., Antonio Lira Pedrín, M., Cerda Contreras, E., Carmona Sánchez, R. I., Guerra López, H., & Solana Ortiz, R. (2020). *Lactobacillus acidophilus* LB: a useful pharmabiotic for the treatment of digestive disorders. *Therapeutic advances in gastroenterology*, 13, 1756284820971201.
<https://doi.org/10.1177/1756284820971201>

Reid G. (1999). The scientific basis for probiotic strains of *Lactobacillus*. *Applied and environmental microbiology*, 65(9), 3763–3766. <https://doi.org/10.1128/AEM.65.9.3763-3766.1999>

Cebeci, A., & Gürakan, C. (2003). Properties of potential probiotic *Lactobacillus plantarum* strains. *Food microbiology*, 20(5), 511-518.

Curk, M. C., Hubert, J. C., & Bringel, F. (1996). *Lactobacillus paraplantarum* sp. nov., a new species related to *Lactobacillus plantarum*. *International Journal of Systematic and Evolutionary Microbiology*, 46(2), 595-598.

Kulp, W. L., & Rettger, L. F. (1924). Comparative study of *Lactobacillus acidophilus* and *Lactobacillus bulgaricus*. *Journal of bacteriology*, 9(4), 357-395.

Shao, Y., Zhang, W., Guo, H., Pan, L., Zhang, H., & Sun, T. (2015). Comparative studies on antibiotic resistance in *Lactobacillus casei* and *Lactobacillus plantarum*. *Food Control*, 50, 250-258.

Mishra, V., & Prasad, D. N. (2005). Application of in vitro methods for selection of *Lactobacillus casei* strains as potential probiotics. *International journal of food microbiology*, 103(1), 109-115.

Capurso L. (2019). Thirty Years of *Lactobacillus rhamnosus* GG: A Review. *Journal of clinical gastroenterology*, 53 Suppl 1, S1–S41. <https://doi.org/10.1097/MCG.0000000000001170>

Rönkä, E., Malinen, E., Saarela, M., Rinta-Koski, M., Aarnikunnas, J., & Palva, A. (2003). Probiotic and milk technological properties of *Lactobacillus brevis*. *International journal of food microbiology*, 83(1), 63-74.

Naghmouchi, K., Belguesmia, Y., Bendali, F., Spano, G., Seal, B. S., & Drider, D. (2020). *Lactobacillus fermentum*: a bacterial species with potential for food preservation and biomedical applications. *Critical reviews in food science and nutrition*, 60(20), 3387–3399. <https://doi.org/10.1080/10408398.2019.1688250>

Ale, E. C., Rojas, M. F., Reinheimer, J. A., & Binetti, A. G. (2020). *Lactobacillus fermentum*: Could EPS production ability be responsible for functional properties?. *Food microbiology*, 90, 103465.

Mu, Q., Tavella, V. J., & Luo, X. M. (2018). Role of *Lactobacillus reuteri* in Human Health and Diseases. *Frontiers in microbiology*, 9, 757. <https://doi.org/10.3389/fmicb.2018.00757>

Oberhelman, R. A., Kosek, M. N., Peñataro-Yori, P., Paredes-Olórtegui, M., & Connolly, E. (2014). A phase one safety study of *Lactobacillus reuteri* conducted in the Peruvian Amazon: Observations from the field. *The American journal of tropical medicine and hygiene*, 90(4), 777–780. <https://doi.org/10.4269/ajtmh.13-0639>

Axelsson, L. (1991). *Lactobacillus reuteri*, a member of the gut bacterial flora: Studies on antagonism, metabolism and genetics.

Oliveira, M., Bosco, N., Perruisseau, G., Nicolas, J., Segura-Roggero, I., Duboux, S., Briand, M., Blum, S., & Benyacoub, J. (2011). *Lactobacillus paracasei* reduces intestinal inflammation in adoptive transfer mouse model of experimental colitis. *Clinical & developmental immunology*, 2011, 807483. <https://doi.org/10.1155/2011/807483sa>

Mayanagi, G., Kimura, M., Nakaya, S., Hirata, H., Sakamoto, M., Benno, Y., & Shimauchi, H. (2009). Probiotic effects of orally administered *Lactobacillus salivarius* WB21-containing tablets on periodontopathic bacteria: a double-blinded, placebo-controlled, randomized clinical trial. *Journal of clinical periodontology*, 36(6), 506-513.

Wu, C. C., Lin, C. T., Wu, C. Y., Peng, W. S., Lee, M. J., & Tsai, Y. C. (2015). Inhibitory effect of *Lactobacillus salivarius* on *Streptococcus mutans* biofilm formation. *Molecular oral microbiology*, 30(1), 16-26.

Corr, S. C., Li, Y., Riedel, C. U., O'Toole, P. W., Hill, C., & Gahan, C. G. (2007). Bacteriocin production as a mechanism for the antinfective activity of Lactobacillus salivarius UCC118. *Proceedings of the National Academy of Sciences*, 104(18), 7617-7621.

Kelesidis, T., & Pothoulakis, C. (2012). Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. *Therapeutic advances in gastroenterology*, 5(2), 111–125. <https://doi.org/10.1177/1756283X11428502>

Czerucka, D., Piche, T., & Rampal, P. (2007). Yeast as probiotics—Saccharomyces boulardii. *Alimentary pharmacology & therapeutics*, 26(6), 767-778.

Dinleyici, E. C., Eren, M., Ozen, M., Yargic, Z. A., & Vandenplas, Y. (2012). Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. *Expert opinion on biological therapy*, 12(4), 395-410.

B. Glueck, Y. Han, G. A. M. Cresci, “Tributyrin Supplementation Protects Immune Responses and Vasculature and Reduces Oxidative Stress in the Proximal Colon of Mice Exposed to Chronic-Binge Ethanol Feeding”, Journal of Immunology Research, vol. 2018, Article ID9671919, 13 pages, 2018. <https://doi.org/10.1155/2018/9671919>

Zhang, W. X., Zhang, Y., Zhang, X. W., Deng, Z. X., Liu, J. X., He, M. L., & Wang, H. F. (2020). Effects of Dietary Supplementation with Combination of Tributyrin and Essential Oil on Gut Health and Microbiota of Weaned Piglets. *Animals : an open access journal from MDPI*, 10(2), 180. <https://doi.org/10.3390/ani10020180>

Sotira, S., Dell'Anno, M., Caprarulo, V., Hejna, M., Pirrone, F., Callegari, M. L., ... & Rossi, L. (2020). Effects of tributyrin supplementation on growth performance, insulin, blood metabolites and gut microbiota in weaned piglets. *Animals*, 10(4), 726.

Miragoli, F., Patrone, V., Prandini, A., Sigolo, S., Dell'Anno, M., Rossi, L., ... & Callegari, M. L. (2021). Implications of Tributyrin on Gut Microbiota Shifts Related to Performances of Weaning Piglets. *Microorganisms*, 9(3), 584.

Yasukawa, Z., Inoue, R., Ozeki, M., Okubo, T., Takagi, T., Honda, A., & Naito, Y. (2019). Effect of Repeated Consumption of Partially Hydrolyzed Guar Gum on Fecal Characteristics and Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled, and Parallel-Group Clinical Trial. *Nutrients*, 11(9), 2170. <https://doi.org/10.3390/nu11092170>

Inoue, R., Sakaue, Y., Kawada, Y., Tamaki, R., Yasukawa, Z., Ozeki, M., Ueba, S., Sawai, C., Nonomura, K., Tsukahara, T., & Naito, Y. (2019). Dietary supplementation with partially hydrolyzed guar gum helps improve constipation and gut dysbiosis symptoms and behavioral irritability in children with autism spectrum disorder. *Journal of clinical biochemistry and nutrition*, 64(3), 217–223. <https://doi.org/10.3164/jcbn.18-105>



Core Nutritionals, LLC
820 N. Pollard St., RTL#3
Arlington, VA 22203
1-888-978-2332

Niv, E., Halak, A., Tiommny, E., Yanai, H., Strul, H., Naftali, T., & Vaisman, N. (2016). Randomized clinical study: Partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome. *Nutrition & metabolism*, 13, 10.
<https://doi.org/10.1186/s12986-016-0070-5>

Ianiro, G., Pecere, S., Giorgio, V., Gasbarrini, A., & Cammarota, G. (2016). Digestive Enzyme Supplementation in Gastrointestinal Diseases. *Current drug metabolism*, 17(2), 187–193.
<https://doi.org/10.2174/138920021702160114150137>

Majeed, M., Majeed, S., Nagabhushanam, K., Arumugam, S., Pande, A., Paschapur, M., & Ali, F. (2018). Evaluation of the Safety and Efficacy of a Multienzyme Complex in Patients with Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Study. *Journal of medicinal food*, 21(11), 1120–1128. <https://doi.org/10.1089/jmf.2017.4172>



CORE NUTRITIONALS
1-888-978-2332

820 N. Pollard St., RTL#3
Arlington, VA 22203

info@corenutritionals.com
www.corenutritionals.com